BeyondSpring announced FDA Fast Track designation for Plinabulin combined with docetaxel to treat advanced non-squamous NSCLC patients after immune checkpoint inhibitor therapy, highlighting unmet medical needs. The company also completed a strategic transaction with Biolin to fund about half of the global Phase 3 DUBLIN-4 trial, enabling data collection from 221 patients in China. Financially, BeyondSpring reported a net loss of $2.1 million in Q3 2026 and is focused on advancing the trial toward an interim analysis that could significantly increase company value.
BeyondSpring's third-quarter 2026 financial results and corporate update provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 14, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 71 rose and 75 fell. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 9.62 with a 5.96% decline and 93% sell order activity, SMMT (Summit Therapeutics Inc) at USD 14.20 down 5.80% with 88% buy order activity, and ALNY (Alnylam Pharmaceuticals, Inc.) at USD 165.74 up 5.80% with 100% buy order activity and a typical hold time of 41 days.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
